01—Abstract
Summary
Summary of the 10-K filed March 9, 1998. Cited figures are marked; the original filing is the authoritative source.
Abbott Laboratories' 1997 Form 10-K (filed March 9, 1998) reports a year of solid growth.
Net sales rose 7.9% to $11.88 billiona, driven by 10.4% volume growth partly offset by a 3.0% unfavorable currency effect. Operating earnings grew 8.9% to $2.85 billion, and net earnings increased 11.3% to $2.09 billion. Diluted EPS was $2.68 versus $2.38 in 1996, a gain of about 12.6%.
Gross margin improved to 57.5%b from 57.0%, helped by product mix, pricing, and productivity. The effective tax rate fell to 29.0% from 29.5%, mainly due to the Taxpayer Relief Act of 1997. The balance sheet strengthened in some areas but tightened in others.
Total assets reached $12.06 billionc, shareholders' investment was $5.0 billion, and cash from operations rose to $2.63 billion. Short-term borrowings climbed to $1.78 billion, largely to fund the roughly $200 million Sanofi parenteral products acquisition and $1.0 billion in capital spending, and long-term debt was roughly flat at $938 million. Abbott returned substantial cash to shareholders through $1.05 billion in share repurchases and $810 million in dividends.
Management reports AAA and Aa1 bond ratings and $1.5 billiond of unused domestic credit lines. The key risks are concentrated in the pharmaceutical franchise. Depakote and Hytrin face patent challenges from generic manufacturers, and Abbott is a defendant in 148 antitrust suits and numerous related cases over prescription drug pricing.
Infant formula antitrust suits and WIC rebate programs also weigh on margins. Management believes none of these matters should have a material adverse effect, though outcomes cannot be predicted. Growth in the Pharmaceutical and Nutritional segment (+9.8%) outpaced Hospital and Laboratory (+5.4%), and a two-for-one stock split was announced for May 1998.
02—Key points
Key Highlights
- Net sales rose 7.9% to $11.88 billion, with volume growth of 10.4% offset by a 3.0% currency drag
- Diluted EPS increased to $2.68 from $2.38 (about 12.6%), and net earnings grew 11.3% to $2.09 billion
- Gross margin expanded to 57.5% from 57.0%, supported by favorable product mix and productivity gains
- Operating cash flow reached $2.63 billion, but short-term borrowings rose to $1.78 billion, up from $1.38 billion
- Capital returns were significant: $1.05 billion in share repurchases and $810 million in dividends paid
- Principal risks include generic challenges to Depakote and Hytrin and 148 antitrust suits over prescription drug pricing
- A two-for-one stock split was announced on February 13, 1998, with distribution scheduled for May 29, 1998
03—Questions
Frequently Asked Questions
What drove Abbott's sales and earnings growth in 1997?
Net sales grew 7.9% to $11.88 billion, led by 10.4% volume growth, with price adding 0.5% and currency subtracting 3.0%. The Pharmaceutical and Nutritional segment grew 9.8%, led by anti-infectives such as Biaxin and adult nutritionals such as Ensure. Hospital and Laboratory products grew 5.4%. Diluted EPS rose to $2.68 from $2.38, helped by higher operating earnings, lower effective tax rate, and gains in other income, including the $189 million share of TAP Holdings.
How significant are the litigation and patent risks?
They are substantial but management does not expect them to be material. Abbott faces 148 federal and state antitrust suits and several investigations over prescription drug pricing, plus infant formula antitrust cases. Depakote and Hytrin, both important products, face patent challenges from generic makers, and the Hytrin compound patent has already expired in the U.S. Management notes that outcomes cannot be predicted with certainty and that the company expects legal proceedings within the next year that could change its reserves.
Is Abbott's balance sheet and liquidity position sound?
Yes, with some shifts to monitor. Abbott holds AAA and Aa1 bond ratings and has $1.5 billion of unused domestic credit lines. Total assets were $12.06 billion and shareholders' investment was $5.0 billion. Short-term borrowings rose sharply to $1.78 billion, mainly to finance acquisitions and capital spending. Long-term debt was about $938 million, and the weighted average short-term interest rate was 6.0%.
How much did Abbott spend on R&D and capital investment, and what do they signal?
R&D spending rose to $1.30 billion, or 11.0% of net sales, up from $1.20 billion in 1996, and it remains focused on pharmaceuticals and diagnostics. Capital expenditures were about $1.0 billion, with a growing share planned for hospital and laboratory products. Together these show Abbott investing heavily in its pipeline and manufacturing capacity, while still generating enough operating cash flow to cover both capital spending and dividends.
What does the stock split and shareholder payout mean for investors?
Abbott announced a two-for-one stock split on February 13, 1998, with an additional share issued for each share held as of May 1, 1998. The 1997 per-share figures were not restated. Dividends declared rose to $1.08 per share from $0.96, and the company repurchased 54.7 million shares over the past three years for $2.6 billion. Shareholders of record numbered 102,981 at year-end 1997.
04—Continue